Shouxiong Huang, Ph.D.
University of Cincinnati
Finding a New TB Vaccine
Mycobacterium tuberculosis (Mtb) infects one-third of the world's population. Multidrug-resistant tuberculosis is present in virtually all countries, leading to an increased risk of failed antibiotic treatment. Development of novel TB vaccines is a global priority to fight tuberculosis. Although the licensed vaccine Bacillus Calmette-Guerin (BCG) has saved many children's lives, its protection against tuberculosis is insufficient. Previous vaccine development mainly focused on conventional T cells such as peptide-stimulated lymphocytes. We will target an unconventional T cell population, called mucosal-associated invariant T (MAIT) cells, which rapidly responds to other bacterial metabolites in early infection. We will determine mycobacterial metabolites for MAIT cell activation to facilitate the development of new TB vaccines.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.